Online Adaptive Radiotherapy for Cervical Cancer

Inclusion Criteria: 1. 18-80 years old; 2. Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma; 3. 2018 FIGO Stage Ib3, II, IIIB and IIIC1 4. Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses) 5. ECOG score 0-2 6. Life expectancy greater than 6 months 7. Ability to remain lying down for more than 30 minutes 8. Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form 9. Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal 10. Must complete baseline assessments and investigations required before treatment before enrolment 11. be eligible for regular follow-up Exclusion Criteria: 1. Have received radiotherapy or chemotherapy in the past 2. Have undergone radical surgery for cervical cancer 3. Have a previous history of malignant tumor 4. Pregnant or lactating women 5. Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.